Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Zhan Yao(Memorial Sloan Kettering Cancer Center), Rona Yaeger(Memorial Sloan Kettering Cancer Center), Vanessa Rodrik-Outmezguine(Memorial Sloan Kettering Cancer Center), Anthony Tao(New York University), Neilawattie M. Torres(Memorial Sloan Kettering Cancer Center), Matthew T. Chang(Memorial Sloan Kettering Cancer Center), Matthias Drosten(Spanish National Cancer Research Centre), HuiYong Zhao(Memorial Sloan Kettering Cancer Center), Fabiola Cecchi(Maryland Oncology Hematology), Todd Hembrough(Maryland Oncology Hematology), Judith Michels(Université Paris-Sud), Hervé Baumert(Hôpital Saint Joseph), Linde A. Miles(Memorial Sloan Kettering Cancer Center), Naomi Campbell(Memorial Sloan Kettering Cancer Center), Elisa de Stanchina(Memorial Sloan Kettering Cancer Center), David B. Solit(Memorial Sloan Kettering Cancer Center), Mariano Barbacid(Spanish National Cancer Research Centre), Barry S. Taylor(Memorial Sloan Kettering Cancer Center), Neal Rosen(Memorial Sloan Kettering Cancer Center)
Nature
August 1, 2017
Cited by 560

Abstract


Related Papers

No related papers found

Powered by citation graph analysis